Pfizer begins testing Covid 19 pills in humans

Pfizer begins testing Covid 19 pills in humans


A US-based pharmaceutical company Pfizer, Covid 19 pills started testing in humans. Pfizer, Covid 19 vaccine BioNTech developed in partnership with. They developed Covid 19 vaccine success rate 95 percent as stated. Thanks to the Covid 19 pill, where Pfizer started human tests, healthcare professionals and early-stage Covid 19 their patients will be protected from the virus.

Covid 19 pills can prevent the virus from reproducing

The pill to prevent the virus from reproducing protease It binds to an enzyme called it. Protease drugs that block the enzyme before, HIV and Hepatitis CIt had been successful in treating other types of viruses, including.

Pfizer Chief Science Officer and President Mikael Dolsten, “SARS-CoV-2It seems likely that access to treatment options will be critical, both now and in the aftermath of the epidemic, given the mutation of said.

Mikael Dolsten

It is stated that the Covid 19 pill developed by Pfizer is the second drug to reach human experiments. The application of antibodies developed previously is rather cumbersome. There are also logistical challenges that make antibodies difficult to use. Early stage thanks to the pill Covid 19 patients stated to be protected from the virus. In addition, healthcare professionals will be able to protect better than Covid 19 by using these pills.

Dolsten said, “If everything goes well PfizerEarly second quarter of 2021 makes 2 hatta makes 3 can start experimenting. The Food and Drug Administration can grant an authorization for early use of the Covid 19 pill based on how the outbreak is progressing. Then the game changes” said.

According to another statement by Mikael Dolsten, Covid 19 pills SARS virus and Successful results against many corona viruses, including MERS. Finally, Pfizer, 6th of April‘gives American Chemical Society in the ball Announces plans to share more data on compound of Covid 19 pill.


Leave a Reply

Your email address will not be published. Required fields are marked *